Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.

Bastin D, Aitken AS, Pelin A, Pikor LA, Crupi MJF, Huh MS, Bourgeois-Daigneault MC, Bell JC, Ilkow CS.

J Immunother Cancer. 2018 Jun 19;6(1):62. doi: 10.1186/s40425-018-0366-2.

2.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaao1641. doi: 10.1126/scitranslmed.aao1641.

PMID:
29298865
3.

Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.

Aitken AS, Roy DG, Martin NT, Sad S, Bell JC, Bourgeois-Daigneault MC.

J Immunother. 2018 Apr;41(3):125-129. doi: 10.1097/CJI.0000000000000208.

4.

Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.

Aitken AS, Roy DG, Bourgeois-Daigneault MC.

Biomedicines. 2017 Jan 4;5(1). pii: E3. doi: 10.3390/biomedicines5010003. Review.

5.

Ku70 Serine 155 mediates Aurora B inhibition and activation of the DNA damage response.

Fell VL, Walden EA, Hoffer SM, Rogers SR, Aitken AS, Salemi LM, Schild-Poulter C.

Sci Rep. 2016 Nov 16;6:37194. doi: 10.1038/srep37194.

6.

Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.

Bourgeois-Daigneault MC, St-Germain LE, Roy DG, Pelin A, Aitken AS, Arulanandam R, Falls T, Garcia V, Diallo JS, Bell JC.

Breast Cancer Res. 2016 Aug 8;18(1):83. doi: 10.1186/s13058-016-0744-y.

Supplemental Content

Loading ...
Support Center